Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LW-402 in Severe Atopic Dermatitis: NCT07370909 Clinical Landscape Report 2026
28 September 2026
NCT07370909 clinical landscape for Severe Atopic Dermatitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GPRC5D CAR-T Cell(Tianjin First Central Hospital) in Recurrent Multiple Myeloma: NCT07365059 Clinical Landscape Report 2026
28 September 2026
NCT07365059 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tacrolimus in Eczema: NCT07367932 Clinical Landscape Report 2026
28 September 2026
NCT07367932 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dupilumab Biosimilar (Chong Kun Dang Pharmaceutical) in Dermatitis, Atopic: NCT07358156 Clinical Landscape Report 2026
28 September 2026
NCT07358156 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclosporine in Acute Myeloid Leukemia: NCT07366801 Clinical Landscape Report 2026
28 September 2026
NCT07366801 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dendritic Cell/AML Fusion Cell Vaccine(Beth Israel Deaconess Medical Center) in Relapsing acute myeloid leukemia: NCT07374029 Clinical Landscape Report 2026
28 September 2026
NCT07374029 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
BCMA-GPRC5D CAR-T(Tongji Hospital) in Multiple Myeloma: NCT07376720 Clinical Landscape Report 2026
28 September 2026
NCT07376720 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
O&D-001 in Refractory Multiple Myeloma: NCT07369895 Clinical Landscape Report 2026
28 September 2026
NCT07369895 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Live Biotherapeutic Preparation (4D Pharma) in Musculoskeletal Diseases: ACTRN12626000112369 Clinical Landscape Report 2026
28 September 2026
ACTRN12626000112369 clinical landscape for Musculoskeletal Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Autologous mesenchymal stem cell therapy (EHL Bio) in Dermatitis, Atopic: NCT07377838 Clinical Landscape Report 2026
28 September 2026
NCT07377838 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Motixafortide in Acute Myeloid Leukemia: NCT07392970 Clinical Landscape Report 2026
28 September 2026
NCT07392970 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GEN-3018 in Acute Myeloid Leukemia: NCT07384715 Clinical Landscape Report 2026
28 September 2026
NCT07384715 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.